About: Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice
Creator	Zhao, Zhendong Hung, Tao Wang, Jianwei Zhou, Hongli Guo, Li Qu, Jianguo Wang, Min
Source	Medline; PMC
abstract	BACKGROUND: Rotavirus (RV) is the main cause of severe gastroenteritis in children. An effective vaccination regime against RV can substantially reduce morbidity and mortality. Previous studies have demonstrated the efficacy of virus-like particles formed by RV VP2 and VP6 (VLP2/6), as well as that of recombinant adenovirus expressing RV VP6 (rAd), in eliciting protective immunities against RV. However, the efficacy of such prime-boost strategy, which incorporates VLP and rAd in inducing protective immunities against RV, has not been addressed. We assessed the immune effects of different regimens in mice, including rAd prime-VLP2/6 boost (rAd+VLP), VLP2/6 prime-rAd boost (VLP+rAd), rAd alone, and VLP alone. RESULTS: Mice immunized with the VLP+rAd regimen elicit stronger humoral, mucosal, and cellular immune responses than those immunized with other regimens. RV challenging experiments showed that the highest reduction (92.9%) in viral shedding was achieved in the VLP+rAd group when compared with rAd+VLP (25%), VLP alone (75%), or rAd alone (40%) treatment groups. The reduction in RV shedding in mice correlated with fecal IgG (r = 0.95773, P = 0.04227) and IgA (r = 0.96137, P = 0.038663). CONCLUSIONS: A VLP2/6 prime-rAd boost regimen is effective in conferring immunoprotection against RV challenge in mice. This finding may lay the groundwork for an alternative strategy in novel RV vaccine development.
has issue date	2011-01-05(xsd:dateTime)
bibo:doi	10.1186/1743-422x-8-3
bibo:pmid	21205330
has license	cc-by
sha1sum (hex)	820f3633db1b3b98889e6a0d257d10d385be85c8
schema:url	https://doi.org/10.1186/1743-422x-8-3
resource representing a document's title	Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice
has PubMed Central identifier	PMC3024956
has PubMed identifier	21205330
schema:publication	Virol J
resource representing a document's body	covid:820f3633db1b3b98889e6a0d257d10d385be85c8#body_text
is schema:about of	named entity 'SEVERE' named entity 'REDUCTION' named entity 'IGA' named entity 'CELLULAR' named entity 'CONCLUSIONS' named entity 'LAY' named entity 'ELICITING' named entity 'VP6' named entity 'EFFICACY' named entity 'REGIMEN' named entity 'FECAL' named entity 'SHEDDING' named entity 'RESULTS' named entity 'INDUCING' named entity 'EFFECTIVE' named entity 'COMPARED' named entity 'PRIME' named entity 'ASSESSED' named entity 'rAd group' named entity 'Rotavirus' named entity 'VLP' named entity 'strategy' named entity 'recombinant' named entity 'VLP' named entity 'immunization' named entity 'rotavirus' named entity 'IMMUNIZATION' named entity 'ROTAVIRUS' named entity 'VACCINATION' named entity 'RAD' named entity 'CHALLENGE' named entity 'REGIMENS' named entity 'BOOST' named entity 'INCLUDING' named entity 'HAVE' named entity 'ROTAVIRUS' named entity 'BACKGROUND' named entity 'VP2' named entity 'EFFECTS' named entity 'PREVIOUS' named entity 'GROUP' named entity 'IMMUNE RESPONSES' named entity 'HIGHEST' named entity 'IMMUNITIES' named entity 'ALTERNATIVE' named entity 'ELICIT' named entity 'FORMED' named entity 'MORBIDITY AND MORTALITY' named entity 'MICE' named entity 'VLP' named entity 'IMMUNIZATION AGAINST' named entity 'ADENOVIRUS' named entity 'BOOSTING' named entity 'VP6' named entity 'PRIME' named entity 'REGIME' named entity 'RECOMBINANT ADENOVIRUS' named entity 'GROUPS' named entity 'STRATEGY' named entity 'FINDING' named entity 'EXPERIMENTS' named entity 'MICE' named entity 'VIRAL SHEDDING' named entity 'REDUCE' named entity 'VIRUS-LIKE PARTICLES' named entity 'VACCINE DEVELOPMENT' named entity 'GASTROENTERITIS' named entity 'DEMONSTRATED' named entity 'NOVEL' named entity 'DIFFERENT' named entity 'FOLLOWED BY' named entity 'CHILDREN' named entity 'IMMUNOPROTECTION' named entity 'IMMUNE' named entity 'MUCOSAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software